InnoStrat Returns from US Bio and ADA Conferences

24 June 2025

InnoStrat has just completed a successful US tour, with Co-founder Jan Kildeskov attending US Bio in Boston and the American Diabetes Association (ADA) conference in Chicago. These two major events brought together some of the most innovative biotech companies and thought leaders, particularly in the fields of diabetes, obesity, and GLP-1-based therapies.

At both conferences, a clear theme emerged: Biotechs are increasingly seeking integrated support across clinical development, Medical Affairs, and commercial strategy, particularly as they prepare for European launch.

“From early development to launch planning, medical leaders are facing unprecedented complexity — especially in crowded therapeutic areas like GLP-1s,” said Jan Kildeskov. “InnoStrat is uniquely positioned to help bridge clinical programs with real-world medical impact and scientific awareness, long before launch.”

Through meetings with biotech innovators at these conferences, InnoStrat strengthened its reputation as a trusted Medical Affairs partner for companies looking to:

• Establish and scale their European medical affairs footprint
• Scientifically differentiate assets in competitive spaces like GLP-1, diabetes, and obesity
• Design evidence and engagement strategies that integrate clinical, medical, and commercial functions

With deep experience in building medical capabilities, shaping scientific narratives, and optimizing launch strategy — all grounded in European regulatory and healthcare realities — InnoStrat brings critical expertise that biotech leaders are looking for in today’s fast-moving environment.

For biotech companies preparing to launch in Europe or looking to enhance their Medical Affairs strategy, InnoStrat stands ready as a science-first, strategy-driven partner.

📩 To learn more or schedule a conversation, reach out to us at info@innostrat.net or connect directly with Jan Kildeskov on LinkedIn.